Maternal folate status and body mass index (BMI) are independent risk factors for neural tube defects (NTD). Population-based studies have identified an inverse association between serum folate and BMI, after adjusting for intake. The objective of this intervention study was to compare the relationship between BMI and the short-term pharmacokinetic response to an oral dose of folic acid. Healthy obese (BMI X30.0 kg m À 2 ; n ¼ 16) and normal-weight (BMI 18.5-24.9 kg m À 2 ; n ¼ 16) women of childbearing age (18-35 years) were administered a single oral dose of folic acid (400 mg). Blood samples were collected over a 10-h period to evaluate the serum folate response. Fasting baseline serum folate was lower in the obese group (P ¼ 0.005); in contrast, red blood cell folate was higher (P ¼ 0.05). Area-under-the-curve for the absorption phase (0-3 h) and peak serum folate concentrations were lower in obese versus normal-weight women (Po0.005). Overall serum folate response (0-10 h) was lower in obese versus normalweight women (repeated-measures ANOVA, P ¼ 0.001). Data suggest body distribution of folate is significantly affected by obesity, and, should pregnancy occur, may reduce the amount of folate available to the developing embryo. These findings provide additional support for a BMI-adjusted folic acid intake recommendation for NTD risk reduction.
INTRODUCTION
Fetal neural tube development is dependent on maternal folate status during the initial weeks of gestation. Periconceptional supplementation with folic acid has been shown to significantly reduce the risk of neural tube defects (NTDs). [1] [2] [3] However, despite supplemental periconceptional folic acid intake and fortification, the risk for an NTD-affected pregnancy is significantly elevated in women with a higher than normal pre-pregnancy body mass index (BMI). The odds for an NTD-affected pregnancy have been estimated by meta-analysis to be 1.22 (overweight), 1.70 (obese) and 3.11 (severely obese) versus normal pre-pregnancy weight. 4 Serum folate concentrations have been inversely associated with BMI (controlled for folate intake) in women of childbearing age in observational studies [5] [6] [7] [8] [9] and with percent body fat in postmenopausal women. 7 These findings provide a basis for the hypothesis that an increase in adiposity impairs folate status, which may be linked to an increase in NTD risk.
The observed inverse relationship between serum folate and BMI is of major public health significance, as 450% of women of reproductive age in the United States are overweight or obese. 10 Currently, the recommended dietary allowance (RDA) for folate is 400 mg dietary folate equivalents/day. Dietary folate equivalents account for the higher bioavailability of folic acid and are calculated as 1.7 Â mg folic acid þ mg food folate. There is an additional recommendation for all women of childbearing age to consume 400 mg folic acid/day to reduce the risk of NTDs. These recommendations are the same for all women regardless of BMI. Furthermore, recommendations were derived based on data from studies conducted 2-3 decades ago, when the average BMI was in the normal range and obesity was not as prevalent. 11, 12 The physiological implications of obesity on folate requirements have not been closely examined and warrant investigation. We hypothesized that obesity would impair the acute pharmacokinetic response to a single dose of folic acid in women of childbearing age.
MATERIALS AND METHODS Participants
Thirty-two healthy adult female subjects (18-35 years old) were recruited and met the following inclusion criteria: Caucasian race; no pregnancy within the past year; no use of dietary supplements within the past 30 days; no chronic disease or prescription drug use; no smoking or heavy alcohol consumption; and no weight change greater than 10% in the past 6 months. Participants had a BMI that was classified either as normal (18.5-24.9 kg m À 2 ) or as obese (X30.0 kg m À 2 ), and were asked to abstain from alcohol consumption and avoid fortified cereals in the week preceding the study.
The University of Georgia Institutional Review Board approved this protocol and all subjects provided written informed consent.
Study design
Participant height and weight were obtained on the study day using standard protocols used for calculation of BMI (kg m À 2 ). Body composition was determined by dual-energy X-ray absorptiometry (Hologic; Delphi A, v11; Bedford, MA, USA).
After an overnight fast, an intravenous catheter was inserted into a suitable vein and blood samples were collected for measurement of baseline serum and red blood cell (RBC) folate concentrations. A 400-mg folic acid dose (Douglas Laboratories, Pittsburgh, PA, USA) was administered orally, and additional blood samples were taken at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9 and 10 h. Participants remained fasting until 3 h, at which time a low-folate snack was consumed. A low-folate lunch and afternoon snacks were also provided.
Participants completed the Automated Self-Administered 24-hour dietary recall (ASA24), 13 including recalls for three separate days (two weekdays and one weekend day).
Analytical methods
The blood folate concentrations were determined by microbiological assay using Lactobacillus rhamnosus.
14, 15 The inter-and intra-assay coefficients of variation were 6.8% and 4.9%, respectively.
Serum folate response was calculated by subtracting the baseline concentrations from the folate value at each subsequent time point. Individual response-time curves were generated and area-under-the-curve (AUC) was calculated using the trapezoidal rule. Maximum concentration response (C max ) and time to peak concentration (t max ) were derived from the individual response curves.
Statistics
Data are reported as means±s.d., except where otherwise indicated. Statistical analyses were performed using SigmaPlot (Systat; Chicago, IL, USA) and SAS (CARY, NC, USA). Differences between biochemical and pharmacokinetic parameters among the normal weight and the obese groups were analyzed using two-tailed t-tests. A linear mixed-effects model was used to describe differences between response-time curves between groups. Subjects were treated as random effects, and an exponential correlation function was used to describe dependence among repeated observations within subjects.
RESULTS
A total of 16 obese and 16 normal-weight women participated in this study. The two groups did not differ in average age or height (Table 1) . Baseline serum folate concentrations were 29% lower in the obese group compared to the normal-weight women. Conversely, the obese women had 14% higher RBC folate concentrations. There were no observed differences between groups in either self-reported total folate intake or in total folic acid intake from fortified foods (n ¼ 14 obese, n ¼ 11 normal weight; data not shown).
Total AUC (0-10 h) was similar in both groups. However, obese and normal-weight women had different overall serum responses to the folic acid dose administered (Po0.001; Figure 1 ). C max was 34% lower in the obese women (23.4 ± 7.1 nmol l ; Po0.005). The average t max for the normal weight was 2.3 h, with all 16 participants reaching C max within the first 3 h, as anticipated. 16, 17 On the other hand, the average t max for the obese group was 3.7 h (range: 1.5-9 h). We therefore calculated AUC 0-3 h, and observed a significantly higher AUC in the normal-weight women compared to the obese group (Figure 2) , suggesting a more rapid folate uptake in the normal-weight women.
DISCUSSION
Recent reports from the National Health and Nutrition Examination Survey (NHANES) indicate that about 70% of all Americans over the age of 20 are overweight or obese. 10 This alarming figure includes 56% of women of reproductive age (20-39 years). 10 With both maternal obesity and low maternal folate status considered risk factors for NTDs, an understanding of the interaction between obesity and folate metabolism becomes essential. The effect of obesity on folate pharmacokinetics has only been evaluated in one previous study, 18 which, similar to our study, monitored serum concentrations of folate up to 10 h following administration of a bolus folic acid dose. In contrast to our study, the folic acid doses in that study were calculated per total body weight, resulting in much higher doses administered with correspondingly higher observed AUCs in the obese versus normal-weight group. Current recommendations do not take body weight into consideration, and advise that women capable of becoming pregnant consume 400 mg of folic acid daily plus folate from a varied diet. 19 Our study provides the first experimental evidence of differences in the pharmacokinetic response to the current recommended dose of folic acid between obese and normal-weight women of childbearing age.
It is unknown whether the lower serum folate concentrations observed in obesity are due to a volumetric dilution of the blood or due to differences in cellular folate uptake influenced by greater adiposity. The higher RBC folate concentration observed here and in NHANES 9 in obese versus normal-weight women provides support for potential differences in cellular uptake. RBC folate concentration is an indicator of long-term folate intake and status, and is considered a marker for tissue concentrations of folate. 19 We observed a difference between obese and normalweight women in the peak serum folate concentration, yet no difference in overall AUC. This observation, together with the higher basal RBC folate concentrations in the obese group, suggests that obesity does not impair the absorption of dietary folate; instead, it may lead to a redistribution of the vitamin from circulation into tissue.
The neural tube develops during the first 28 days of gestation when nutrients are derived from maternal serum; therefore, the data from this investigation suggest that obesity may result in reduced folate availability during early embryonic development should pregnancy occur. These findings support conclusions from population-based studies that obese women of reproductive age may require higher folic acid intakes to reduce NTD risk. This study is the first to provide evidence of a negative impact of obesity on the metabolic response to the current recommended intake of folic acid for NTD risk reduction. As low maternal vitamin B12 status has also been shown to be a risk factor for NTDs, independent of folate status, 20 additional studies are needed to determine the overall impact of obesity on vitamin B12 status of women of childbearing age and the potential contribution of vitamin B12 status to the obesity-associated differences in folate pharmacokinetics. Further studies are also required to clarify the relationship between obesity and long-term folate pharmacokinetics. Such investigations would provide definitive evidence of the metabolic fate of folate in obese women and provide additional support for revised folate/folic acid intake recommendations for women of reproductive age.
